Abstract:Cancer is a perilous life-threatening disease, and attempts are constantly made to create multinuclear transition metal complexes that could lead to potential anticancer medications and administration procedures. Hence, this work aims to design, synthesize, characterize, and assess the anticancer efficacy of ruthenium p-cymene complexes incorporating N, N'- bis(4-substituted benzoyl)hydrazine ligands. The formation of the new complexes (Ru2H1-Ru2H3) has been thoroughly established by elemental analysis, FT-IR, UV-vis, NMR, and HR-MS spectral techniques. The solid-state molecular structures of the complexes Ru2H1 and Ru2H3 have been determined using the SC-XRD study, which confirms the N, O, and Cl-legged piano stool pseudo-octahedral geometry on each ruthenium(II) ion. The stability of these complexes in the solution state and their lipophilicity profile have been determined. Further, the titled complexes were tested for their in vitro anticancer activity against the cancerous H460 (lung cancer cells), SkBr3 (breast cancer cells), HepG2 (liver cancer cells), and Hela (cervical cancer cells) along with non-cancerous (HEK-293) cells. The IC50 results revealed that complex Ru2H3 exhibits potent activity against the proliferation of all four cancer cells and outscored the effect of standard metallodrug cisplatin. This may be attributed to the presence of a couple of lipophilic electron-donating methoxy groups in the ligand scaffold and also the ruthenium(II) p-cymene motifs. Advantageously, all the complexes (Ru2H1-Ru2H3) displayed cytotoxic specificity only towards the cancerous cell by leaving the off-target non-cancerous cells undamaged. Acridine orange/ethidium bromide (AO/EB) staining, Hoechst 33342, Mitochondrial Membrane Potential (MMP), and Reactive Oxygen Species (ROS) staining assays were used to investigate the apoptotic pathway and ROS levels in mitochondria. The results of Western blot analysis confirmed that complexes triggered apoptosis through intrinsic mitochondrial pathway by upregulating Bax and downregulating Bcl-2 proteins. Finally, the extent of apoptosis triggered by complex (Ru2H3) was quantified with the aid of flow cytometry using the Annexin V-FITC/propidium iodide (PI) double-staining technique.

Nanoscaled Carborane Ruthenium(ii)-Arene Complex Inducing Lung Cancer Cells Apoptosis

Ruthenium Complexes as Promising Candidates against Lung Cancer

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Exploring the Cytotoxicity of Dinuclear Ru(II) p-cymene Complexes Appended N,N'-Bis(4-substituted benzoyl)hydrazines: Insights into the Mechanism of Apoptotic Cell Death

Ligand-Based Neutral Ruthenium(Ii) Arene Complex: Selective Anticancer Action

Study on antitumor activity of three ruthenium arene complexes in vitro

Ruthenium(II) complexes as mitochondrial inhibitors of topoisomerase induced A549 cell apoptosis

Dinuclear arene ruthenium(II) arylthiourea complexes: Synthesis, structure, cancer cell growth inhibition and apoptosis induction studies

Cyclometalated Ru(II)-NHC Complexes with Phenanthroline Ligand Induce Apoptosis Mediated by Mitochondria and Endoplasmic Reticulum Stress in Cancer Cells

Lysosome-targeted ruthenium(II) complexes induce both apoptosis and autophagy in HeLa cells

The ruthenium complex assists in nuclear targeting and selective killing of tumor cells

Ruthenium compounds: Are they the next‐era anticancer agents?

The Anti-proliferative Effect, Apoptotic Induction, and Cell Cycle Arrest of Tetra Halo Ruthenate Nanocomposites in Different Human Cancer Cell Lines

Mechanistic Studies of Arene-Ruthenium(II) Complexes with Carbothioamidopyrazoles as Alternative Cancer Drugs

Cu(II)-Coordination Polymer Nanostructures Induce Human Lung Cancer Cell Carcinoma Apoptotic Cell Death In Vitro and In Vivo

A dual-targeting ruthenium nanodrug that inhibits primary tumor growth and lung metastasis via the PARP/ATM pathway

New ruthenium polypyridyl complexes functionalized with fluorine atom or furan: Synthesis, DNA-binding, cytotoxicity and antitumor mechanism studies

A coordinated ruthenium-rifampicin complex reprogramming the colon carcinoma micro-environment mediated by modulation of p53/AkT/mTOR/VEGF pathway

Systematic evaluation of the antitumor activity of three ruthenium polypyridyl complexes

Antimetastatic activity of (arene)ruthenium(II) complex of 4-aryl-4H-naphthopyran

pH‐Responsive, Self‐Assembled Ruthenium Nanodrug: Dual Impact on Lysosomes and DNA for Synergistic Chemotherapy and Immunogenic Cell Death